Boehringer Ingelheim Pharma v EUIPO - Glenmark Pharmaceuticals Europe (Forme d'inhalateur) (EU trade mark - Judgment) [2024] EUECJ T-524/23 (13 November 2024)

Boehringer Ingelheim Pharma v EUIPO - Glenmark Pharmaceuticals Europe (Forme d'inhalateur) (EU trade mark - Judgment) [2024] EUECJ T-524/23 (13 November 2024)

The Board of Appeal correctly identified the essential characteristics of the contested mark and established, based on patents and objective analysis, that these characteristics were necessary to achieve the technical result of inhaling a medical substance. The overall convex shape was not an independent essential...

Source-derived case information.

Citation
[2024] EUECJ T-524/23
Parties
Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG; Respondent: European Union Intellectual Property Office (EUIPO); Intervener: Glenmark Pharmaceuticals Europe Ltd
Jurisdiction
European Union
Procedural Posture
Action for Annulment / Final Judgment
Outcome
Action dismissed
Legal Topics
EU Trade Mark, Invalidity Proceedings, Three Dimensional Mark, Technical Function Exclusion, Costs
Intellectual Property European Union Law EU Trade Mark Invalidity Proceedings Three Dimensional Mark Technical Function Exclusion Costs

Source-derived case record

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Downloadable case file Legal principles 4 Authorities cited 19 Party arguments 2
Sign in to unlock

Parties

Boehringer Ingelheim Pharma GmbH & Co. KG

Applicant

European Union Intellectual Property Office (EUIPO)

Respondent

Glenmark Pharmaceuticals Europe Ltd

Intervener

Procedural Posture

Action for Annulment / Final Judgment

  1. 1 Whether the contested three-dimensional EU trade mark consists exclusively of the shape of goods necessary to obtain a technical result under Article 7(1)(e)(ii) of Regulation No 40/94
  2. 2 Whether the Board of Appeal erred in its identification of essential characteristics and technical function
  3. 3 Whether the Board of Appeal's reasoning was internally inconsistent in violation of Article 94 of Regulation 2017/1001

Ratio Decidendi

The Board of Appeal correctly identified the essential characteristics of the contested mark and established, based on patents and objective analysis, that these characteristics were necessary to achieve the technical result of inhaling a medical substance. The overall convex shape was not an independent essential characteristic, nor a major arbitrary element. The Board of Appeal's reasoning was consistent and complied with the obligation to state reasons. The action is dismissed in its entirety.

Court Disposition

Action dismissed

Orders

  • Boehringer Ingelheim Pharma GmbH & Co. KG to pay the costs